Discounted Cash Flow (DCF) Analysis Levered
Sequana Medical NV (SEQUA.BR)
2.46 €
+0.02 (+0.00%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 1.03 | 0.97 | 0.96 | 0.37 | 0.92 | 1.11 | 1.33 | 1.60 | 1.93 | 2.32 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -9.88 | -18.48 | -17.01 | -23.62 | -27.48 | -31.03 | -37.32 | -44.88 | -53.97 | -64.91 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.04 | -0.33 | -0.14 | -0.33 | -0.68 | -0.47 | -0.57 | -0.69 | -0.82 | -0.99 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -9.91 | -18.82 | -17.14 | -23.94 | -28.16 | -31.50 | -37.89 | -45.57 | -54.80 | -65.90 |
Weighted Average Cost Of Capital
| Share price | $ 2.46 |
|---|---|
| Beta | 0.741 |
| Diluted Shares Outstanding | 22.77 |
| Cost of Debt | |
| Tax Rate | -1.27 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 7.803 |
| Total Debt | 17.59 |
| Total Equity | 56.01 |
| Total Capital | 73.61 |
| Debt Weighting | 23.90 |
| Equity Weighting | 76.10 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 1.03 | 0.97 | 0.96 | 0.37 | 0.92 | 1.11 | 1.33 | 1.60 | 1.93 | 2.32 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.88 | -18.48 | -17.01 | -23.62 | -27.48 | -31.03 | -37.32 | -44.88 | -53.97 | -64.91 |
| Capital Expenditure | -0.04 | -0.33 | -0.14 | -0.33 | -0.68 | -0.47 | -0.57 | -0.69 | -0.82 | -0.99 |
| Free Cash Flow | -9.91 | -18.82 | -17.14 | -23.94 | -28.16 | -31.50 | -37.89 | -45.57 | -54.80 | -65.90 |
| WACC | ||||||||||
| PV LFCF | -29.41 | -33.01 | -37.06 | -41.60 | -46.70 | |||||
| SUM PV LFCF | -187.79 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.13 |
| Free cash flow (t + 1) | -67.22 |
| Terminal Value | -1,310.38 |
| Present Value of Terminal Value | -928.63 |
Intrinsic Value
| Enterprise Value | -1,116.42 |
|---|---|
| Net Debt | -1.28 |
| Equity Value | -1,115.13 |
| Shares Outstanding | 22.77 |
| Equity Value Per Share | -48.97 |